Approximate rates of ischemic stroke and a neutral effect on clinically defined major adverse cardiovascular events and all causes of mortality were reported, comparing dual (NOAK + P2Y12 inhibitor) and triple therapy (VKA + P2Y12 inhibitor + Aspirin), (Table 1) [51,52,53,54]. Here, P2RY12 is linked to ischemic stroke.